Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NVDA
7. NRIX
8. SPY
9. OIG
10. BAC

Go back to Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025 7:00 AM EDT

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI... More